Alamar Biosciences began trading on Nasdaq after pricing a $220 million IPO, signaling continued demand for proteomics platforms that can move toward regulated diagnostics. The company plans to support a clinical version of its Argo HT instrument and expects to file a 510(k) submission for FDA clearance next year. Alamar said it will use proceeds to expand commercial infrastructure and grow assay content across areas including oncology, cardiology, metabolic disease, and health monitoring. It also plans a lower-cost Argo HT variant to widen the install base in smaller laboratories. The offering highlights how proteomics hardware and assay ecosystems are increasingly structured for dual-use deployment in both research and clinical settings.